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ABSTRACT. We evaluated the effect of NQO1 genetic variation on 
PAH-DNA adducts in esophageal squamous cell carcinoma (ESCC) in 
northeast Iran. Golestan Province in northeast of Iran has one of the 
highest esophageal cancer incidences in the world. The study included 
93 ESCC cases and 50 control individuals who were seen at the clini-
cal cancer center in Golestan province. NQO1 C609T genotypes were 
determined by PCR-RFLP analysis. NQO1 gene expression in tissue 
samples was determined by quantitative real-time PCR. Immunohisto-
chemical techniques were used to detect PAH-DNA adducts in ESCC 
and normal esophageal tissues. The distributions of NQO1 genetic poly-
morphism between cases and the control group were not significantly 
different. NQO1 gene expression was not higher in tumor tissues than in 
normal esophageal tissues adjacent to the ESCC; expression was higher 
in tumor tissues that had the NQO1 T allele. NQO1 gene expression was 
high in normal esophageal tissues. The level of PAH-DNA adducts was 
significantly higher in ESCC tissues of cases than in normal tissues ad-
jacent to tumor tissues and in normal esophageal tissues of healthy con-
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trols. There were no significant differences between the adduct levels 
of normal esophageal tissues of patients and controls. There was also 
no significant relationship between cigarette smoking and PAH-DNA 
adducts. We concluded that PAHs are a risk factor for ESCC and that 
PAH-DNA adducts have potential as a biomarker for risk of ESCC. 
Key words: NQO1; Esophageal squamous cell carcinoma (ESCC); 
Northeast Iran; PAH-DNA adduct
INTRODUCTION
The sixth most common cause of cancer mortality worldwide is esophageal cancer 
(Parkin et al., 2001). Golestan Province in Northeast Iran is among the highest esophageal 
cancer incidence areas in the world and the age-standardized rate for this cancer is over 100 in 
100,000 for both genders (Mahboubi et al., 1973). The geographical differences of esophageal 
squamous cell carcinoma (ESCC) incidences depend on environmental and genetic factors 
(D’Errico et al., 1999).
Polycyclic aromatic hydrocarbons (PAHs) consist of several linked benzene struc-
tures, which are generated during incomplete combustion and pyrolysis of organic substances 
(Poirier, 2004). A remarkable number of human cancers are known to be related to exposure to 
PAHs, like other chemical carcinogens (Bartsch, 2000; Hecht, 2003; Poirier, 2004), which can 
induce mutations in human cells (Mahboubi et al., 1973; Bartsch, 2000; Poirier, 2004). PAHs 
are also produced during high-temperature cooking, cigarette smoking and organic fuel burn-
ing (Elovaara et al., 2007). The vast environmental distribution of PAHs results in a great deal 
of human exposure to them. Also because of their lipophilic nature, PAHs are easily absorbed 
and distributed in the whole human body (Franco et al., 2008). PAHs are metabolized by xe-
nobiotic metabolizing enzymes, which convert xenobiotic compounds into more hydrophilic 
and polar metabolites for their easier excretion in human body fluids. Urine samples from indi-
viduals who live in Northeast Iran have been shown to contain high levels of 1-hydroxypyrene 
glucuronide (1-OHPG). This compound is the urine metabolite of benzo[α]pyrene (Kamangar 
et al., 2005; Fagundes et al., 2006). Also, high levels of PAHs were observed in mate beverage 
in high prevalent areas for ESCC in Brazil; mate herb leaves are dried by hot wood smoke 
or burning gas or oil, so that these dried leaves become highly rich in PAH compounds (Ka-
mangar et al., 2008). Additionally, it has been shown that residents of Golestan Province have 
high levels of 1-OHPG as a PAH biomarker in urine samples. These results were reported by 
the Digestive Diseases Research Center of Tehran University of Medical Sciences, where this 
finding did not differ by gender, age or habitation whether rural or urban, and interestingly, 
there were no differences regarding cigarette smoking habits (Kamangar et al., 2005). 
One of the most important of these enzymes is NADP(H):quinone oxidoreductase 
1 (NQO1) (Shimada, 2006). However, in the process of these metabolic reactions, some un-
stable PAH metabolites are highly reactive and may attack the DNA molecule, which results 
in the formation of PAH-DNA adducts (Poirier, 2004; Shimada, 2006). 
NAD(P)H:quinone oxidoreductase, which was first called DT-diaphorase, has the 
ability to detoxify a large number of environmental and synthetic carcinogens (Zhang et 
al., 2003b; Sarbia et al., 2003). A polymorphism of C to T in the 609th codon of NQO1 
241PAH-DNA adduct and NQO1 in ESCC from Iran
©FUNPEC-RP www.funpecrp.com.brGenetics and Molecular Research 9 (1): 239-249 (2010)
DNA leads to the formation of the NQO1*2 allele, which is markedly weak in its bio-
chemical activity. The NQO1 T allele has only 2-4% enzymatic activity in comparison 
to its wild-type form. Cells homozygous for the polymorphic NQO1 allele (T/T) express 
NQO1 mRNA, but they have no detectable NQO1 protein because the mutant NQO1 
protein is rapidly degraded by the proteasomal system (Siegel et al., 2001). This C to 
T substitution causes a proline to serine change in the 187th amino acid location of the 
NQO1 protein sequence. A relationship between NQO1 T allele and upper gastrointestinal 
malignancies has been shown (Zhang et al., 2003a). The heterozygous phenotype for the T 
allele for NQO1 gene has 3-fold weaker enzyme activity, and that homozygous for T allele 
has almost complete enzyme activity loss (Zhang et al., 2003b). NQO1 gene expression 
is stimulated by oxidative compounds such as PAHs and also antioxidants (Long et al., 
2001). Additionally, it is elevated in some human cancers such as breast, colon, and lung, 
and normally in the human body, stomach and trachea have the highest levels of NQO1 
expression (Sharp et al., 2000; Kolesar et al., 2002; Cleton-Jansen et al., 2008). 
We conducted a study to evaluate the effect of NQO1 genetic variation on PAH-DNA 
adducts in ESCC from Northeast Iran because no PAH-DNA adduct and NQO1 genetic varia-
tion data are available in the literature on tumors from this region. We analyzed NQO1 genetic 
variation in 93 patients and 50 healthy individuals and PAH-DNA adducts in 29 ESCC; 29 
normal adjacent tumor tissues and 27 normal esophageal tissues from healthy individuals (the 
tissues from paraffin blocks were available). Additional tumor and normal tissues from frozen 
samples were available for 11 patients and 5 healthy individuals, allowing the NQO1 gene 
expression assessment (by quantitative real-time polymerase chain reaction, PCR). The data 
for the NQO1 gene expression in tumor and normal tissues were compared with the result of 
NQO1 variation and PAH-DNA adducts.
MATERIAL AND METHODS
We examined 93 cases including 52 males and 41 females with a mean age of 65.04 ± 
11.21 years, who were the patients with ESCC where their malignancy was confirmed by en-
doscopy (clinically) and pathology (tissue diagnosis) (Table 1). The area of study was Northeast 
Iran, Golestan Province, where almost 50% of inhabitants are Turkmen. The cases were referred 
by local physicians to Atrak Clinic in Khatam Hospital at Gonbad City, which is a special center 
for gastroesophageal cancers. ESCC cases for the study were enrolled between the years 2002 
and 2008. The criteria for enrollment were an age of at least 18 years and be resident of the study 
area at registration time, with no concurrent or previous history of other cancer in any organ. 
Also, 50 controls with no malignancy and/or severe diseases, including 22 males and 28 females, 
with a mean age of 61.26 ± 10.36 years (Table 1) were enrolled from Atrak Clinic in Khatam 
Hospital at Gonbade Kavous City in Golestan Province, between the years 2002 and 2008, with 
the same age and residence criteria as for the cases. These controls came to the clinic for regular 
gastrointestinal check-ups or consultations for some non-serious gastrointestinal problem. 
According to Table 1, the mean age was 61.26 ± 10.36 years for the control group and 
65.04 ± 11.21 for the case group, P = 0.049. Of the total sample population (143), 93 (65%) 
were cases and 50 (35%) were controls. With regard to gender distribution, 28 (56%) of con-
trols were females and 22 (44%) were males and in the case group, 41 (44.1%) were females 
and 52 (55.9%) were males (P = 0.17). The cases and controls were referred to the Atrak Clinic 
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in Khatam Hospital at Gonbad City of Golestan Province in Northeast Iran between the years 
2002 and 2008, and their minimum age for enrollment was 18 years. Demographic character-
istics of cases and controls are categorized in Table 1.
Genomic DNA of cases and controls was obtained from whole blood samples by 
the QIAGEN Flexigen kit for blood samples. The extracted DNA was then kept in a -20°C 
freezer until further use.
NQO1 polymorphism genotyping by PCR was performed in a 25-µL reaction volume 
containing 100 ng genomic DNA and 0.5 mL 10 pM forward and reverse primers, 2.5 µL 10X 
PCR buffer, 1.25 U Taq DNA polymerase, 0.8 µL 10 mM MgCl
2
, and 0.5 µL 0.1 mM of each 
dNTP. The primers were F: 5’-AAGCCCAGACCAACTTCT-3’ and R: 5’-ATTTGAATTC 
GGGCGTCTGCTG-3’. The thermocycling program consisted of an initial denaturation for 14 
min at 94°C followed by 40 cycles at 94°C for 1 min for denaturation, 56°C for 1 min for an-
nealing and 72°C for 2 min for extension. The PCR product was a 172-bp amplicon. The PCR 
product was digested by 20 U Hinf1 enzyme (Fermentas) for 3 h at 37°C, and the digestion 
product was then run on a 3% agarose gel. The normal NQO1 allele (C) is not cut by the Hinf1 
enzyme at the polymorphic site, but the polymorphic T allele is cut into 131- and 41-bp bands. 
Thus, the homozygous wild-type (C/C) individuals have one band, homozygous polymorphic 
(T/T) individuals have two bands, and the heterozygote (C/T) individuals have three bands. 
Of the 93 ESCCs examined in this study for the NQO1 genetic polymorphism, fro-
zen samples of 11 ESCC cases (11 of tumor and 11 of normal adjacent to the tumor tissues) 
and 5 normal tissues from healthy controls were available for evaluation of mRNA expres-
sion for NQO1 gene. Esophageal tumor and normal tissues were taken from ESCC patients 
and healthy controls by endoscopic biopsy, and then, the samples immersed in RNA solution 
(QIAGEN) for RNA preservation, where the tissue-containing tubes were kept in a -70°C 
freezer for later use. RNA extraction was performed by the QIAGEN RNeasy Kit, and the 
RNA samples were kept at -70°C. 
For analysis of NQO1 gene expression we used the real-time PCR method with the 
Roche Lightcycler apparatus. Real-time PCR were carried out in a 25-μL reaction volume in 
Roche capillaries. The reaction mixture contains 0.5 μL TaKaRa Ex.taq and 12.5 μL TaKaRa 
one-step Master mix, and 0.5 μL TaKaRa RT primers, 7.5 μL TaKaRa RNase-free DI water, for-
ward and reverse NQO1 RT primers, each one 10 pmoL, and 2 μL tissue total RNA containing 
250 ng total tissue mRNA. For internal control, we used β-actin for normalizing the expression 
values between all samples and obtaining comparative expression values relative to β-actin.
Primers for the reactions were NQO1: forward: 5’-AAGCAGTGCTTTCCATCA-3’ 
and reverse: 5’-TCCTGCCTGGAAGTTTAG-3’, which give a 283-bp amplicon, and for β 
actin: forward: 5’-GAGACCTTCAACACCCCAGCC-3’ and reverse: 5’-AGACGCAGGAT 
GGCATGGG-3’, which give a 140-bp amplicon.
For each of the real-time amplifications, we prepared a standard curve by running 
real-time PCR with five 10-fold diluted cDNAs as template for NQO1 and β-actin, separately.
Therefore, in each run for samples we had reactions for NQO1 and β-actin for every 
sample and one standard sample for NQO1, one standard sample for β-actin, and also a nega-
tive control for NQO1 and a negative control for β-actin. NQO1 to β-actin comparative values 
were obtained as final expression values for each of the tumor tissues and the normal tissues, 
both for cases and healthy controls. NQO1:real-time program consisted of three phases; a 
reverse transcription phase for 5 min at 42°C, then an amplification-quantification phase of 50 
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cycles of one denaturation step at 95°C for 5 s and one elongation step at 60°C for 35 s, and a 
final phase of melting by increasing the temperature from 65° to 100°C in 15 s. 
Of the 93 ESCCs examined in this study for the NQO1 genetic polymorphism, paraffin 
blocks of 29 ESCC cases (tumor and normal adjacent to tumor tissues) and 27 normal tissues from 
healthy controls were available for PAH-DNA adduct analysis. Esophageal tumor and normal 
tissues were taken from ESCC patients and healthy controls by upper GI endoscopy performed 
by expert GI specialists. The samples were stored in 10% formalin and then prepared to make 
paraffin-embedded blocks. Tissue sections (3 µm) were applied to precoated glass slides, and 
after dewaxing were subjected to microwave antigen retrieval in citrate buffer. To block nonspe-
cific reactivity and staining from endogenous peroxidase, sections were incubated in hydrogen 
peroxide (0.3%) for 30 min and normal goat serum (10%) for 30 min. After rinsing, slides were 
incubated overnight at 4°C with primary anti-BPDE-DNA antibody; 8e11 (HM5008, HBT-Cell 
Sciences, dilution 1:100). After washing with PBS, the secondary antibody (InvisionTM mouse) 
was added to the slides. Finally, DAB kit was applied to the samples with an incubation of 10 
min. The control-positive and control-negative samples were kindly prepared by our colleagues 
at the International Agency for Research on Cancer, Lyon, France. The percentage of positive 
PAH-DNA adduct-stained nuclei was the basis for our scoring of the samples for PAH-DNA 
adduct levels; the score 0 was given for no staining samples, score 1 for 1-10% positive-stained 
nuclei, score 2 for 11-50% stain, and score 3 for 51% or more positive-stained nuclei (Lai et al., 
2006). The results of the immunohistochemistry (IHC) scores were compared between cases 
and controls. In this study, ESCC tissues and normal esophageal tissues of 29 cases (tumor and 
normal adjacent tumor tissues) and normal esophageal tissues of 28 controls were analyzed by 
IHC, and also, the results of IHC were compared to the individuals’ cigarette smoking habits.
Statistical analysis
For comparison of NQO1 gene expression means, we used the Student t-test, and ANOVA 
was applied for comparison of multiple groups in regard to their quantitative expression levels. 
For genotype distribution analysis, the chi-square test for qualitative variables was performed. The 
chi-square test was also used for Hardy-Weinberg analysis of the observed and expected genotype 
frequencies. The statistical method applied for comparing PAH-DNA adduct levels between the 
tissues was the Fisher exact test. A 5% probability level was taken as statistically significant in this 
study, and the odds ratio (OD) was calculated with 95% confidence interval (CI). All statistical 
analyses were performed using the SPSS software (version 15).
RESULTS
According to Table 1, mean age was 61.26 ± 10.36 years for the control group and 
65.04 ± 11.21 for the case group, P = 0.049. Of the total sample population (143), 93 (65%) 
were cases and 50 (35%) were controls. For gender distribution, 28 (56%) of controls were 
females and 22 (44%) were males, and in the case group, 41 (44.1%) were females and 52 
(55.9%) were males (P = 0.17). The cases and controls were referred to Atrak Clinic, Khatam 
Hospital in Gonbad City of Golestan Province in Northeast Iran between the years 2002 and 
2008, and their minimum age for enrollment was 18 years. Demographic characteristics of 
cases and controls are shown in Table 1.
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Table 1. Age and gender distribution of cases and controls of the study.
Cases (N = 93) Controls (N = 50) P
Age (years, mean ± SD) 
Female (N, %) 
Male (N, %) 
65.04 ± 11.21 
41 (44.1%) 
52 (55.9%) 





The NQO1 T/T genotype frequency was compared between cases and the control 
group, and this difference was not significant (P = 0.448, χ2 = 1.605; Table 2). The observed 
values of genotype percentages was 0.9999 for the case group and 1.00 for the control group, 
which correlated with Hardy-Weinberg equilibrium (P ≥ 0.05).
Table 2. NQO1 genetic polymorphism among esophageal squamous cell carcinoma cases and controls.
C/C 
NQO1 C609 polymorphism
C/T T/T T allele frequency
Cases     51 (54.8%)    35 (37.6%)    7 (7.5%)    49 (26.3%)
Controls  22 (44%) 24 (48%) 4 (8%) 32 (32%)
Total       73 (51.04%)      59 (41.25%)     11 (7.89%)       81 (28.32%)
(χ2 = 1.605, P = 0.448). Data are reported as number with percent in parentheses.
NQO1 gene expression was analyzed for normal tissues adjacent to the tumors of cases 
(0.00329 ± 0.00095) and controls (0.00272 ± 0.00132), and there was no significant difference 
between the two groups (P = 0.234). Tumor tissue expression of NQO1 was compared to that of 
normal tissues, and this analysis showed no significant variation between the two groups (P = 
0.128). This finding was also analyzed with a non-parametric method, and the result was similar 
to that for the parametric one (P = 0.286). NQO1 gene expression was analyzed for its relationship 
with the NQO1 C609T genotype; in normal tissues there was no relationship of the genotype with 
gene expression (P = 0.39). In tumor tissues, however, there was an almost significant relationship 
with NQO1 genotype and NQO1 gene expression (P = 0.062; Table 3). In our investigation, we 
found that ESCC samples with T allele (TT or CT genotypes) had higher NQO1 gene expres-
sion than the samples with CC genotype (P = 0.01). This value shows a significant linearity and 
a meaningful trend from C/C to C/T and T/T genotypes and increasing NQO1 gene expression. 
NQO1 C609T genotype Case Control
Tumor Normal (adjacent to tumor) Normal
C/C 0.0022 0.0034 0.0039
(N = 4) (N = 4) (N = 2)
C/T 0.0067 0.0034 0.0021
(N = 6) (N = 6) (N = 2)
T/T 0.011 0.0018 0.0016
(N = 1) (N = 1) (N = 1)
Mean 0.0066 0.0028 0.0025
Table 3. Means of NQO1 gene expression and genotypes for tissues of cases and controls.
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All adduct scorings of the samples with their numbers are shown in Table 4. The ma-
jority of positive samples were in the 1 scoring category.
Tissue Score 0 Score 1+ Score 2+ Score 3+
Tumor PAH-DNA  adducts (29 cases) 15 13 0 1
Case normal esophageal tissue PAH-DNA adducts (29 cases) 27   0 0 2
Control esophageal tissue PAH-DNA adducts (27 controls) 26   0 1 0
Tumor adducts were significantly compared to normal tissues of cases (P = 0.0008). The odds ratio was 12.6 with 
95%CI of 2.31-63.8. The difference between ESCC tissues and normal esophageal tissues of the healthy controls 
was statistically significant (P = 0.0002). Odds ratio = 24.26; 95%CI = 2.89-203.48.
Table 4. The number of samples with their scores of adduct levels for tumor tissues, normal esophageal tissue 
adjacent to tumors and normal esophageal tissues of healthy controls. 
PAH-DNA adducts in ESCC tissues were compared to the normal esophageal tissues 
in the same cases. Tumor adducts were significantly higher compared to normal tissues of 
cases (P = 0.0008), where the OD = 12.6 and 95%CI = 2.31-63.8. 
Adduct levels in ESCC tissues were statistically significant (P = 0.0002) compared with 
the normal esophageal tissues of healthy controls, with an OD = 24.26 and 95%CI = 2.89-203.48. 
The normal esophageal tissue adducts of cases were compared to those of healthy controls, 
but there was no significant difference in adduct levels between the two groups (P = 0.9). In regard to 
the levels of adducts in cigarette smokers, in the case group the PAH-DNA adducts of tumor nuclei 
showed no significant difference between smokers and non-smokers (P = 0.5). In normal esophageal 
tissues, adduct levels showed no significant difference between smokers and non-smokers (P = 0.3).
Because the polymorphisms of the genes of four xenobiotic-metabolizing enzymes 
(NQO1, CYP2C9, GSTT1, and GSTM1) of cases and controls had been analyzed before and 
were available, these polymorphisms were evaluated for any relationship between them and 
the adduct levels. We examined whether PAH-DNA adduct levels are higher in polymorphic 
allele-containing genotypes or not.
In our study population, there were three genotypes for the NQO1*2 allele: wild-type 
homozygote (C/C), heterozygote (C/T) and polymorphic homozygote (T/T) genotypes. We 
compared PAH-DNA adduct levels in ESCC tissues and esophageal normal tissues in the 
three NQO1*2 allele genotypes, and no significant differences were seen in the tumor tissue 
analysis (P = 0.9) and in the normal esophageal tissue analysis (P = 0.3) in the adduct levels 
between the three genotypes (C/C, C/T, T/T).
In the evaluation of NQO1 enzyme polymorphism with occurrence of PAH-DNA adduct, 
we did not find any relationship between the polymorphic genotypes and adduct levels, and thus, 
maybe some other enzymes are involved in the elimination of xenobiotics preventing adduct forma-
tion. Also, we did not find a significant difference by comparing PAH-DNA adduct levels in healthy 
control normal esophagus tissues versus normal esophageal tissues adjacent to ESCC of the patients.
DISCUSSION
In regard to NQO1 gene polymorphisms, a study performed by Zhang et al. (2003b) on the 
relationship of the NQO1 T allele with the risk for ESCC and gastric cardiac adenocarcinoma in north 
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China, showed that the T/T genotype was significantly more prevalent in case groups than in controls, 
and it was suggested that this genotype may represent a higher risk of ESCC and gastric cardiac ad-
enocarcinoma. However, in the present study, we did not see a significant difference between case and 
control groups in their T/T genotype frequencies. Even the C/T genotype was more frequent in the 
control group than in the case group, but this difference was also not of statistical value. Thus, it seems 
that having the NQO1 T allele is not a predisposing genetic risk factor in Northeast Iran.
In another study in China and Germany, the T/T genotype has been shown to pose a 
significant risk for developing ESCC (Zhang et al., 2003a).
To understand the effect of the genetic polymorphisms investigated on susceptibility 
to esophageal cancer, we suggest future studies with patients in other cities with different risks 
of ESCC to compare with our results.
In this study, we noticed that NQO1 relative to β-actin gene expression is not higher in 
ESCC than in normal esophageal tissues; these findings are not in agreement with the studies per-
formed on breast, colon and lung carcinomas. In a classification of esophageal tissue expression 
results in relation to their underlying NQO1*2 allele (C609T) genotypes, we found that in esopha-
geal tumor tissues NQO1 gene expression is elevated as the T allele emerges in the genotype. That 
is, we found more expression in C/T genotypes than in C/C genotypes and even more expression 
in the T/T genotype compared to C/T genotypes. In C/C genotype tumors, NQO1 gene expression 
was not significantly higher than in normal esophageal tissues adjacent to the tumors. In normal 
esophageal tissues, we did not see an association between the presence of NQO1 T allele and 
NQO1 gene expression. Zhang et al. (2003a) reported a gradual decrease in NQO1 protein ex-
pression in C/T to T/T genotypes in comparison to C/C genotypes of ESCC using an IHC method. 
Sarbia et al. (2003) reported such pattern of NQO1 protein expression in esophageal adenocarci-
noma by IHC, but no relationship of NQO1 genotypes with NQO1 mRNA expression was found. 
In the present study, NQO1 gene expression was analyzed at the mRNA level, and the results may 
differ from what was found in the studies that determined expression at the protein level. 
In the majority of human body tissues, the expression of NQO1 is at minimal levels. 
This low level of expression is kept under negative control by Nrf3 transcription factor, where-
as the other close relative to it, the Nrf2 transcription factor, has a positive effect on NQO1 
gene expression. Both transcription factors attach to the ARE element on the NQO1 promoter 
and control the expression process of the gene downstream (Sankaranarayanan and Jaiswal, 
2004). NQO1 gene expression increases in response to oxidant and electrophilic radicals to 
counteract oxidative and electrophilic stresses, and in fact, this is a kind of chemopreventive 
defense mechanism for cells (Sankaranarayanan and Jaiswal, 2004).
It seems that the high gene expression of NQO1 in tumor cells is due to increased cel-
lular metabolism in malignancy, as we know that tumor cells are at a really augmented level 
of proliferation and metabolism, which gives rise to many oxidative radicals and stressing 
cellular wastes, thus triggering the synthesis of a battery of chemoprotective enzymes such 
as NQO1 and GSTs, HO1, and γ-GCS against stressors such as reactive oxygen species (San-
karanarayanan and Jaiswal, 2004). The impaired levels of NQO1 protein may induce the cell 
to express more NQO1 mRNA. It was shown that NQO1 stabilizes p53 protein and helps the 
integrity of cell cycle (Sankaranarayanan and Jaiswal, 2004). 
In the presence of NQO1 T allele, the protein’s life span becomes too short, and the 
NQO1 level in the cell is near zero. This lack of the protein stimulates the cell to keep the 
NQO1 transcription at an elevated level to compensate for the lack of the protein, which seems 
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to be more exaggerated in the case of the T/T genotype. Besides, these cells try to save their 
p53 proteins by the aid of their NQO1 protein, but there is no present and active NQO1, so 
again, the NQO1 promoter remains at an active level.
In this study, we did not find tumor tissues with NQO1 expression higher than that 
of normal tissues, but when we compared the expression between three genotypes of tumor 
esophageal tissues, C/C and C/T and T/T, we found a progressive increase in NQO1 expres-
sion. As the tissue becomes malignant, its genotype may affect its NQO1 expression.
The elevated NQO1 expression in tissues that have low expression in their normal 
states may be a valuable diagnostic key for alteration in the normal cell cycle and its deviation 
toward a carcinogenesis process.
Further studies are needed to reveal how NQO1 gene expression in tissues differs 
based on their biological state, normal or tumor, and their genotype, and if this expression 
changes in metaplasias representing an alarm for on-going malignant changes. 
Archival paraffin-embedded tissue blocks are shown to be suitable sources for evalu-
ation of PAH-DNA adducts as a good biomarker of exposure (van Gijssel et al., 2004). Ciga-
rette smoke is a rich source of many PAHs (Bartsch, 2000; Akpan et al., 2006), so the relation 
of cigarette smoking and PAH-DNA adduct levels was also investigated in this study.
We supposed that PAH-DNA adducts are a risk factor for ESCC, because they are 
easily distributed throughout the human body (Wang et al., 2008). PAHs can be converted 
by cellular enzymes to DNA-reactive products, which have the capability to attach to DNA 
molecules and to be inserted in place of nucleotides. Especially if a combination of genotypes 
of polymorphic nucleotide excision repair genes exists in a person, the presence of PAH-DNA 
adducts may be a risk for breast cancer (Crew et al., 2007). Our data showed that the number 
of PAH-DNA adducts is remarkably high in ESCC tissues compared to normal esophageal 
tissues of the same cases and esophageal tissues of healthy controls. When we compared 
the normal esophageal tissues of the cases and controls, there was no significant difference 
between the two groups, a finding that suggests that the presence of PAH-DNA adducts is a 
phenomenon that is related to ESCC carcinogenesis.
Nonetheless, our study cases and controls are both from one geographical region, and 
the adduct levels are high in the cases. In a study on ESCC in China (van Gijssel et al., 2002), 
the adduct levels were higher in cases than in controls but the habitation area of cases was a 
high ESCC prevalent area in China and the controls were from the United States.
Another study on colon cancer has mentioned the relationship between PAH-DNA 
adducts and colon cancer risk (Al-Saleh et al., 2008).
Some studies based on immunological techniques have examined the relationship be-
tween breast cancer and PAH-DNA adducts (Santella et al., 2000; Tang et al., 2003; Crew et 
al., 2007; Sagiv et al., 2009; McCarty et al., 2009). There were no strong statistical values 
confirming the relationship between cigarette smoking and increased risk of PAH in breast 
cancer (Santella et al., 2000). We could not find any significant effect of cigarette smoking on 
PAH-DNA adduct levels and ESCC risk.
Contrary to our findings on ESCC, some studies on the role of PAHs in prostatic 
cancer do not strongly support the role of PAHs in prostatic cancer risk (Rybicki et al., 2004; 
John et al., 2009).
According to the Digestive Diseases Research Center of Tehran University of Medi-
cal Sciences, the measure of high levels of 1-OHPG in northeastern areas of Iran suggests an 
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extensive and high exposure to PAHs in the region’s inhabitants, and this finding did not differ 
by gender and age and habitation whether rural or urban; interestingly, there were no differ-
ences regarding cigarette smoking habits (Kamangar et al., 2005). 
The smoking habits of cases and controls showed no relationship between cigarette 
smoking and levels of PAH-DNA adducts. 
In conclusion, our findings demonstrate the role of PAHs as a risk factor of ESCC and 
the potential of PAH-DNA adducts for being a biomarker of risk for ESCC. Although we could 
not find any significant relationship between cigarette smoking and the adducts, we suggest 
that this subject be investigated with greater sample sizes and more quantitative methods for 
human and environmental samples.
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